<p>
    Immune Checkpoint Therapy:
</p>
<p>
    Immune Checkpoint Inhibitor (ICI) Therapy (Prior to Liver Tx):
</p>
<ul>
    <li data-list-item-id="e0fb63fdc5cffe76298a3aef8a01fd24c">
         All patients with hepatocellular carcinoma (HCC) beyond the Milan criteria should be considered for ICI therapy for the following reasons:
        <ul>
            <li data-list-item-id="e20d961de3257105d0ee935cb0da4488a">
                 High response rates observed with ICI in combination with other loco-regional treatments (LRT)
            </li>
            <li data-list-item-id="ee0441f942bc554cd56f249bf271d0bf2">
                 Reduced risk of post-transplant recurrence (due to more effective tumor down staging) as shown in current literature.
            </li>
        </ul>
    </li>
    <li data-list-item-id="e10c03be9af45067b916b12395d244bfa">
         Patients on ICI before transplant should be listed on hold. &nbsp;
    </li>
    <li data-list-item-id="eb3fdfc242b05f37f6476fd1b893b1d47">
         Patients with exceptional responses to immuno-oncology (IO) based combinations can be considered as candidates for liver transplantation (downstaging)
    </li>
    <li data-list-item-id="ee737fe74648acc5a3d760beba5f8901a">
         Patients with vascular invasion should be included in the downstaging trial.
    </li>
    <li data-list-item-id="e9bd5081a1e3a6f0ee7470fa45a9a5dc7">
         ICI should be stopped when exceptional MELD reaches 28 points for Blood Groups A, B, O (for AB dependent on the number of patients on the waitlist). &nbsp;
    </li>
    <li data-list-item-id="eb629a43124e3eb2a8a9f9bc4522647bb">
         Patient can be activated 6 weeks after stop of ICI. &nbsp;
        <ul>
            <li data-list-item-id="e5d37f72a8ea1de79e84e1e1da928e570">
                 Physician should clarify on admission for transplant when the last dose of ICI was given.
            </li>
        </ul>
    </li>
</ul>
<p>
    <strong>Washout Period</strong>: If liver transplantation is done after downstaging therapy with ICI wait time should be <strong>minimally 6 weeks</strong>, best 12 weeks before transplant.
</p>
<p>
    If transplant occurs &lt;6 weeks after ICI:
</p>
<ul>
    <li data-list-item-id="e48d0983bb9e02af48b4da6a02a0e84b1">
         <strong>Pre-transplant</strong>: Consider plasmapheresis (PLEX), IVIG
    </li>
    <li data-list-item-id="e4d648a02fa8684d9d81fb8d3e2955a81">
         <strong>Induction</strong>: Simulect on day 0 and 4, IVIG on days 5 and 10
    </li>
    <li data-list-item-id="eccd822af13c73a1d2f7a8e87116716d6">
         Start tacrolimus (target trough 8–10 ng/mL) pre-op
    </li>
    <li data-list-item-id="eb0415949ea09768733804aed044cd6d2">
         Myfortic 540 mg
    </li>
    <li data-list-item-id="e43de2080f85ba813580dd2577b60fff1">
         Maintain prednisone 7.5 mg for 6 months post-op
    </li>
</ul>
<p>
    Immune Checkpoint Inhibitor (ICI) Therapy (After Liver Tx):
</p>
<ul>
    <li data-list-item-id="e42402ecdb142c0e1d4475b14f379257d">
         HCC: Due to rejection risk, ICI should be considered after phase-3 evidence treatments (Sorafenib, Lenvatinib, Cabozantinib, Regorafenib, Folfox)
        <ul>
            <li data-list-item-id="e0a6c6fd95dc42e3f9be5c1b299ef5a61">
                 ICI use selectively in patients with expected high response rate:
                <ul>
                    <li data-list-item-id="eddc76fc6e04b75a3659c9c5e6e170f30">
                         Melanoma - up to 50% response rate
                    </li>
                    <li data-list-item-id="e81e58c4fc0a4771177bed2c84329c0b5">
                         Non-small cell lung cancer (NSCLC) – 20-45% response rate
                    </li>
                    <li data-list-item-id="e5ec0a9f92c3f6f31d5d98288908afd0a">
                         Renal cell carcinoma (RCC)
                    </li>
                    <li data-list-item-id="e10381cee9062c81a2b7c5c908554826c">
                         Urothelial carcinoma
                    </li>
                    <li data-list-item-id="efe84fc4c84249d0aef1fe5ce8dabb339">
                         Microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors – 30-50% response rate
                    </li>
                </ul>
            </li>
        </ul>
    </li>
    <li data-list-item-id="e7910ae7f6097a236ba167eb13658c840">
         Inform patients about increased risk of rejection (20-40%), possible organ loss/death
    </li>
    <li data-list-item-id="ec1b25f2f8c969dc2cc867db55d340140">
         Avoid dual checkpoint inhibition &nbsp;
    </li>
    <li data-list-item-id="e26bc8036429f6d063cfa433bc047a28f">
         Prednisone ≤10 mg is considered safe with ICI (does not impact effectiveness)&nbsp;
    </li>
</ul>